-
Endpoints News2 weeks ago
Immutrin secures $86M for antibody program
A British biotech based in Cambridge, England, raised $86 million to advance an antibody drug designed to deplete protein deposits in people with amyloidosis. The company,...
-
Endpoints News2 weeks ago
Novartis to invest $480M in China following AstraZeneca and Lilly pledges
Novartis is the latest drugmaker to invest in its Chinese footprint, with a pledge of more than 3.3 billion yuan ($480 million) to bolster two manufacturing...
-
Endpoints News2 weeks ago
CEO and C-suite are out in battle for control of Aurinia
Biotech takeover specialist Kevin Tang is consolidating control at Aurinia Pharmaceuticals, and has replaced the CEO and C-suite at the company, according to a securities filing...
-
Endpoints News2 weeks ago
Dizal’s first-line lung cancer data; Sanofi expands in China
Plus, news about Opdivo: 📊 Dizal drug succeeds in Phase 3 lung cancer study: The drug Zegfrovy improved progression-free survival compared to chemo in first-line non-small...
-
Endpoints News2 weeks ago
Apogee shares positive mid-stage maintenance data for eczema drug that could challenge Dupixent, Ebglyss
Apogee Therapeutics said its moderate-to-severe eczema candidate could offer much more convenient dosing over standard treatments based on its latest mid-stage results. Monday’s Phase 2 maintenance...
-
Endpoints News2 weeks ago
Arikayce could become Insmed’s second blockbuster following late-stage win in lung infection
Insmed’s Phase 3 trial win for Arikayce in a particular kind of lung infection sets up the drug to expand into the front-line setting — possibly...
-
Endpoints News2 weeks ago
Sanofi extends $180M to California T cell engager startup Kali
Sanofi is back in the T cell engager business after a couple years of fluctuating interest, extending its support to a relatively unknown California startup in...
-
Endpoints News2 weeks ago
Pfizer’s Lyme disease vaccine trial hampered by lack of cases
Pfizer’s final-stage trial of its long-awaited Lyme disease vaccine missed its primary endpoint, but the drugmaker said it still plans to try to take the experimental...
-
Endpoints News2 weeks ago
Roche, Nvidia’s ‘AI Factory’; Industry looks to soften MFN impact; Structure’s oral GLP-1 data; and more
Welcome to another edition of Endpoints Weekly — and happy spring! The weather may not feel very spring-like here in NYC (outside that false start a...
-
Endpoints News3 weeks ago
FDA seeks input on Makary’s voucher pilot
The FDA is seeking feedback ahead of a public meeting this summer to evaluate the progress of a voucher pilot that has so far accelerated four...
Sanofi Bispecific Scores in Asthma, Rhinosinusitis, but Eczema Bet Doesn’t Pay Off
